BR112012008649A2 - Composição farmacêutica e usos da referida composição - Google Patents

Composição farmacêutica e usos da referida composição

Info

Publication number
BR112012008649A2
BR112012008649A2 BR112012008649A BR112012008649A BR112012008649A2 BR 112012008649 A2 BR112012008649 A2 BR 112012008649A2 BR 112012008649 A BR112012008649 A BR 112012008649A BR 112012008649 A BR112012008649 A BR 112012008649A BR 112012008649 A2 BR112012008649 A2 BR 112012008649A2
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
pharmaceutical
pharmaceutical compositions
administration
Prior art date
Application number
BR112012008649A
Other languages
English (en)
Portuguese (pt)
Inventor
Danping Li
S Burak Eric
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Publication of BR112012008649A2 publication Critical patent/BR112012008649A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012008649A 2009-10-13 2010-10-12 Composição farmacêutica e usos da referida composição BR112012008649A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25102309P 2009-10-13 2009-10-13
PCT/US2010/052263 WO2011046905A2 (en) 2009-10-13 2010-10-12 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112012008649A2 true BR112012008649A2 (pt) 2021-11-03

Family

ID=43876821

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008649A BR112012008649A2 (pt) 2009-10-13 2010-10-12 Composição farmacêutica e usos da referida composição

Country Status (16)

Country Link
US (2) US20120208857A1 (enExample)
EP (2) EP2488175A4 (enExample)
JP (3) JP2013507443A (enExample)
KR (1) KR101791709B1 (enExample)
CN (1) CN102573840A (enExample)
AU (2) AU2010307054A1 (enExample)
BR (1) BR112012008649A2 (enExample)
CA (1) CA2776310A1 (enExample)
EA (1) EA022765B1 (enExample)
IL (1) IL219018A (enExample)
MX (1) MX337145B (enExample)
NZ (1) NZ599151A (enExample)
PH (1) PH12012500695A1 (enExample)
SG (1) SG10201406571YA (enExample)
UA (1) UA111145C2 (enExample)
WO (1) WO2011046905A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027791B1 (ru) 2010-11-24 2017-09-29 Мелинта Терапьютикс, Инк. Фармацевтические композиции
CN104784113B (zh) * 2015-04-30 2017-09-29 成都国为生物医药有限公司 一种含有利奈唑胺的组合物及其制备方法
US11112370B2 (en) * 2019-01-04 2021-09-07 The Boeing Company Reconfigurable backscatter detector

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY127336A (en) * 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
PE20011088A1 (es) * 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
MY137618A (en) * 2000-08-22 2009-02-27 Pharmacia Corp Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US20060270680A1 (en) * 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ,インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2007133803A2 (en) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2008085913A1 (en) 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections

Also Published As

Publication number Publication date
EP3095445A1 (en) 2016-11-23
PH12012500695A1 (en) 2024-02-12
MX2012004282A (es) 2012-05-22
KR101791709B1 (ko) 2017-10-30
CN102573840A (zh) 2012-07-11
SG10201406571YA (en) 2014-11-27
EA022765B1 (ru) 2016-02-29
KR20120099676A (ko) 2012-09-11
EP2488175A2 (en) 2012-08-22
WO2011046905A3 (en) 2011-10-20
WO2011046905A2 (en) 2011-04-21
EP2488175A4 (en) 2013-08-07
EA201270547A1 (ru) 2012-12-28
IL219018A (en) 2016-11-30
US20120208857A1 (en) 2012-08-16
JP2017141285A (ja) 2017-08-17
AU2010307054A1 (en) 2012-04-26
NZ599151A (en) 2014-07-25
US20150165040A1 (en) 2015-06-18
MX337145B (es) 2016-02-15
JP2013507443A (ja) 2013-03-04
CA2776310A1 (en) 2011-04-21
UA111145C2 (uk) 2016-04-11
AU2016234893A1 (en) 2016-10-20
JP2015155479A (ja) 2015-08-27
IL219018A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BRPI1012219A2 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
IN2012DN02805A (enExample)
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
MX2011009847A (es) Agentes antihelminticos y su uso.
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
BR112014026058A2 (pt) composições para tratamento tópico de infecções microbianas
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0921705B8 (pt) composição farmacêutica antimicrobiana e seu uso
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
TR201004464A2 (tr) Kemik erimesi için formülasyon.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25E Requested change of name of applicant rejected

Owner name: RIB-X PHARMACEUTICALS, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870170066753 DE08/09/2017 DEVIDO AO DESPACHO PUBLICADO NA RPI 2669 DE 03/03/2022.